VA
GRTX

VR Adviser’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

VR Adviser’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-917,860
Closed -$9.39M – 30
2020
Q4 		$9.39M Buy
917,860
+866,207
+1,677% +$9.47M 1.38% 18
2020
Q3 		$467K Buy
+51,653
New +$409K 0.09% 21

Other funds holding GRTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser's GRTX Position: Q1 2021 in Review

VR Adviser sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2021, closing a stake of 917,860 shares — an estimated $9.39M sold.

VR Adviser first reported a position in GRTX in Q3 2020 and held it in 2 quarters. The position peaked at $9.39M in Q4 2020. 54 funds tracked by Wall St. Rank hold GRTX as of Q1 2021.

  • VR Adviser reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • VR Adviser sold 917,860 Galera Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $9.39M.
  • VR Adviser first reported a position in Galera Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • VR Adviser's Galera Therapeutics, Inc. Common Stock position peaked at $9.39M in Q4 2020.
  • 54 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2021.

Based on VR Adviser's 13F filing for Q1 2021, filed 14 May 2021.